The Michael J. Fox Foundation continually strives to communicate our scientific progress -- at meetings, as well as through peer-reviewed scientific publications.
December 02, 2014
Lorraine Lacovitti, Xiaotao Wei, Jingli Cai, Eric W. Kostuk, Ruihe Lin, Alexander Gorodinsky, Philip Roman, Gretchen Kusek, Sonal S. Das, Audrey Dufour, Terina N. Martinez, and Kuldip D. Dave
Parkinson disease (PD) is the second leading neurodegenerative disease in the US. As there is no known cause or cure for PD, researchers continue to investigate disease mechanisms and potential new therapies in cell culture and in animal models of PD. In PD, one of the most profound...Read More
Characterization, comparison, and cross-validation of in vivo alpha-synuclein models of parkinsonism.
November 17, 2014
Terina. N. Martinez1, Michael Sasner2, Mark T. Herberth3, Robert C. Switzer III4, S.O. Ahmad5, Kelvin C. Luk6, Sylvie Ramboz7, Andrea E. Kudwa7, Deniz Kirik8, Joe Flores8, Ronald J. Mandel9, Matthew P. Getz9, Ryan Brown9, Joshua C. Grieger10, R. Jude Samulski10, David Dismuke10, Sonal S. Das11, Mark A. Frasier1, and Kuldip D. Dave1
1The Michael J. Fox Foundation for Parkinson' s Research, 2The Jackson Laboratory, 3WIL Research, 4NeuroScience Associates, 5Saint Louis University,...Read More
Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable
July 02, 2014
Journal of Parkinsons Disease
Cognitive impairment is a common occurrence in Parkinson's disease (PD), although the severity and specific presentation varies across patients. Initial deficits, including mild cognitive impairment (PD-MCI), may remain stable or in many cases, may progress over variable lengths of time to Parkinson's disease dementia (PDD). As there are currently no marketed treatments for milder forms of cognitive impairment, an opportunity exists to defin...Read More
June 24, 2014
Annals of Clinical and Translational Neurology
Repurposing Food and Drug Administration (FDA)-approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer's Drug Discovery Foundation (ADDF) and the Michael J. Fox Foundation for Parkinson's Research (MJFF) convened an advisory panel in October 2013 to understand stakeholder perspe...Read More
The BioFIND Study (Fox Investigation For New Discovery Of Biomarkers In Parkinson's Disease): Design And Methodology (P4.043)
April 08, 2014
Movement Disorders: Parkinson's Disease Biomarkers
OBJECTIVE:To describe the study design of BioFIND, an observational, cross-sectional, multi-center study of biomarkers in moderate to advanced Parkinson's disease (PD) and healthy control (HC) subjects.
BACKGROUND:PD-specific biomarkers will greatly aid clinicians' ability to diagnose the disease and monitor and/or predict its progression as well as provide a critical tool for therapeutic trials. However, prior studies ...Read More